Radiopharm Theranostics Sees Revenue Growth Amid Increased Losses

Radiopharm Theranostics Limited (AU:RAD) has released an update.

Radiopharm Theranostics Limited reported a significant revenue increase by 100% to $299,228 for the fiscal year ended June 30, 2024, while also experiencing a 38.5% rise in net loss to $47,949,119, attributed to escalated clinical trial and research activities. Despite the revenue growth, the company saw a decrease in net assets and did not declare any dividends for the year, continuing the trend from the previous year. The company’s increased research efforts and changes in intangible assets and liabilities have impacted its financial position, with details to be fully disclosed in the audited financial statements by September 30, 2024.

For further insights into AU:RAD stock, check out TipRanks’ Stock Analysis page.